Blockbusters win PBS berths

Posted 26 February 2021 PM

Sanofi's blockbuster eczema drug Dupixent has finally been given a PBS greenlight and will be listed from Monday.

After languishing for 12 months following a positive recommendation last March, the biologic will be subsidised for the treatment of patients with chronic severe atopic dermatitis who gained inadequate benefit from topical therapies.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here